States May Use ICER to Target ‘Unsupported’ Drug Price Hikes With Chart: Seven of 10 Drugs Saw Price Hikes Without Novel Clinical Evidence, ICER Reports

Editor’s Note: A quotation from Philip Ball has been updated to clarify that he was describing drug manufacturers’ criticisms of ICER, not his own.

As states continue their quest to lower prescription drug prices for the benefit of their budgets and residents, a small but growing number are considering legislation that would levy an 80% tax on drug price increases that the Institute for Clinical Effectiveness Research (ICER) deems “unsupported” by clinical evidence.

© 2021 MMIT

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/Drug_Benefits_Life_Sciences.jpg
November 23

Will ‘Build Back Better’ Spell Disaster for Pharma Innovation?

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-health-plan-weekly-Wall-Street-Isnt-Sweating-Cignas-Third-Quarter-MLR-Miss.jpg
November 23

Big Three PBMs’ 3Q Results Make Up for Insurer Disappointments

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured_AdobeStock_442155384.jpg
November 23

SCAN Health Opts to Invest in Medication Adherence Tool

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today